Exclusive

Exclusive Ed Silverman

STAT Plus: CVS and its PBM agree to pay $45 million to Illinois for failing to pass drug rebates

Exclusive Lizzy Lawrence

STAT Plus: Jeff Shuren, medical devices head at FDA, to leave the agency

Exclusive Timmy Broderick

STAT Plus: Wastewater surveillance group funded by Google founder, Bloomberg sheds dozens of testing sites

Exclusive Megan Molteni

STAT Plus: Broad Institute, facing end of Microsoft cloud contract, shuffles data science leadership

Exclusive Mohana Ravindranath

STAT Plus: Startup Q Bio raises $27 million to build its own full-body scanner

Exclusive Nicholas Florko

STAT Plus: Applesauce lead contamination could not have been prevented, top FDA official suggests

Exclusive Mohana Ravindranath

STAT Plus: A cancer care startup is making a new bet with payers and providers: only pay if it works

Exclusive Nicholas Florko

STAT Plus: Top FDA officials weighing regulation of ultra-processed foods, internal documents show

Exclusive Nicholas Florko and J. Emory Parker

STAT Plus: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors

Exclusive Brittany Trang and Mohana Ravindranath

STAT Plus: Top Biden administration officials withdraw from Coalition for Health AI

Exclusive Allison DeAngelis

STAT Plus: Biotech accelerator Curie.Bio extends its reach with new $380 million fund

D.C. Diagnosis Sarah Owermohle

STAT Plus: Senators push Medicare for a PET scan pay bump

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests

Exclusive Ed Silverman

STAT Plus: Doctors Without Borders is closing its widely regarded access-to-medicines campaign

Exclusive Casey Ross

STAT Plus: Republican lawmakers criticize FDA’s partnership with CHAI on regulating AI in medicine

Exclusive Rachel Cohrs Zhang

Biden and Trump are fighting to claim credit for $35 insulin. It was actually a pharma giant’s idea

Exclusive Brittany Trang

STAT Plus: New AI for biopsies can analyze microscopy images, talk to pathologists about your tumor

Exclusive John Wilkerson

NIH wanted to make cancer research more diverse. The effort turned out to be a costly failure

Exclusive Olivia Goldhill

STAT Plus: The inside story of how Lykos’ MDMA research went awry

Exclusive Betsy Ladyzhets

NIH documents show how $1.6 billion long Covid initiative has failed so far to meet its goals

Exclusive Rachel Cohrs Zhang

STAT Plus: PBM executives invited to testify before House panel

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: BIO lays off 30 employees, including senior leaders

Exclusive Jonathan Wosen

STAT Plus: Element Biosciences, an Illumina rival, on its genomics ambitions — and why it hasn’t gone public

Exclusive Nicholas Florko

STAT Plus: NYU professors who defended vaping didn’t disclose ties to Juul, documents show

Exclusive Adam Feuerstein

STAT Plus: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition

Exclusive Megan Molteni

Early tests of H5N1 prevalence in milk suggest U.S. bird flu outbreak in cows is widespread

Exclusive Matthew Herper

STAT Plus: Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future

Exclusive John Wilkerson

STAT Plus: Takeda is fourth big company to leave BIO since December

Exclusive Katie Palmer

STAT Plus: Accreditation agencies take on telehealth with new virtual care standards